The origin of next generation medicines
We are accelerating drug discovery to deliver treatments to patients faster.
Our powerful engine integrates combinatorial chemistry, pico-scale activity-based screening, and AI, generating millions of empirical datapoints every week to evolve our models.
This enables our biologists and medicinal chemists to discover novel small molecule therapeutics rapidly.
In the news
Powering the AI Revolution for Drug Discovery with High-Quality Empirical Data
In this webinar, 1859 will discuss its approach to rapidly generating high-quality, empirical, small molecule datasets, and its comparison to other approaches, like public data curation and traditional screening technology. In addition, the panel will walk through case studies that show how this data accelerates drug discovery at Hit ID through Lead OP.
GRC High Throughput Chemistry and Chemical Biology
The High Throughput Chemistry and Chemical Biology GRC is a premier, international scientific conference focused on advancing the frontiers of science through the presentation of cutting-edge and unpublished research, prioritizing time for discussion after each talk and fostering informal interactions among scientists of all career stages.
1859 Strengthens Leadership with Appointment of Consulting CSO and Strategic Pharma Advisors, Bringing Deep Oncology and Immunology Expertise
1859 is pleased to announce the appointment of Jeff Hager, Ph.D., as Consulting Chief Scientific Officer (CSO), and Michael Howell, Ph.D., and Venkat Reddy, Ph.D., as Strategic Pharma Advisors.